St. Jude Medical and CardioMEMS today announced U.S. Food and Drug Administration (FDA) approval of the CardioMEMS™ HF System, the first and only FDA-approved heart failure monitoring system proven to significantly reduce heart failure hospital admissions and improve quality of life in NYHA class III patients. St. Jude Medical has a 19 percent ownership of CardioMEMS and intends to immediately exercise its exclusive option to purchase the remaining portion of the company.
Meta Keywords
CardioMEMS, ST. Jude Medical, acquisition, Healthcare Professionals, Patients